Biotech company BPC Instruments is publishing preliminary figures for the first quarter of 2026, indicating a weaker operating profit than expected. This is stated in a press release. The earnings development during the first quarter of 2026 has been negatively affected by lower sales combined with a higher cost base as a result of investments in the business carried out over the past year. Net sales amounted in the first quarter preliminarily to SEK 12.49 million (13.05), and operating profit to SEK -0.58 million (0.95). - The outcome in the first quarter of 2026 has been weaker than expected. Over the past year, we have made investments to strengthen the organization, our offering and our long-term capacity. At the same time, customers' decision-making processes during the quarter have taken longer than usual, which has affected both sales and earnings during the quarter. We continue to see a clear interest in our solutions, but the uncertainty in the market has made it more difficult to close deals at the pace we had expected, says Jing Liu, CEO of BPC Instruments.The interim report will be released as planned on Wednesday, May 6.